Sinopep-Allsino Bio Pharmaceutical Co., Ltd.SSE: 688076

Report for Q3 2025

Oct 23, 2025 · Issued by Sinopep-Allsino Bio Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 23, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-702

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. on 6ix

Earlier from Sinopep-Allsino Bio Pharmaceutical

Announcement on Voluntary Disclosure of Earnings Preannouncement for Q3 2025Oct 11, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025Sep 6, 2025
2025 Semi-annual ReportAug 21, 2025
Announcement on Voluntary Disclosure of Passing cGMP Site Inspection for DrugsAug 6, 2025
Announcement on the Voluntary Disclosure of Receiving Drug Registration Certificates for Sequiretic Acetate Injection and Agomelatine TabletsAug 1, 2025

Later from Sinopep-Allsino Bio Pharmaceutical

Announcement on Voluntary Disclosure of Agomelatine Tablets Prospective Winning of the 11th National Centralized Drug ProcurementOct 29, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Atosiban Acetate InjectionDec 10, 2025
Announcement on Receiving the Decision of Administrative PenaltyDec 18, 2025
Announcement on Progress in Signing a Major Daily Operation ContractDec 31, 2025
Announcement on Using Idle Raised Funds for Cash ManagementJan 17

All Sinopep-Allsino Bio Pharmaceutical news releases

Follow Sinopep-Allsino Bio Pharmaceutical into a list and get an email when it puts out news.

Follow Sinopep-Allsino Bio Pharmaceutical